SABS — SAB Biotherapeutics Share News
0.000.00%
Last trade - 00:00- $276.60m
- $177.17m
SAB Biotherapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Ferrari, Hawkeye 360, Micron Technology
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies
U.S. STOCKS ON THE MOVE-InspireMD, MiniMed, SoFi Technologies
U.S. STOCKS ON THE MOVE-Tencent, Air Products, Protagonist
U.S. STOCKS ON THE MOVE-Lululemon, Swarmer, DocuSign
SAB Biotherapeutics slips on $85 mln equity offering
Brief: Sab Bio Announces Pricing Of $85 Million Public Offering Of Common Stock At $3.85 Per Share
SAB Biotherapeutics falls after launching stock offering
Brief: Sab Bio Strengthens Board Of Directors With Appointment Of New Chair And New Director
Brief: Sab Biotherapeutics Files For Offering Of Up To $300 Mln
Brief: SAB Biotherapeutics Enters Sales Agreement With UBS Securities - SEC Filing
Brief: Sab Bio Announces Positive Confirmatory Clinical Results
SAB Biotherapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: SAB BIO Reports Strong Cash Position With Completed Financing Extending Operational Runway
SAB Biotherapeutics Inc expected to post a loss of 80 cents a share - Earnings Preview
SAB Biotherapeutics Inc expected to post a loss of $1.16 a share - Earnings Preview
Brief: SAB Biotherapeutics Appoints New Chief Financial Officer
Brief: SAb Biotherapeutics Rebrands As SAB BIO